Get started

Biotechnology

Healthcare Critical LevelTechnical Analysis The 200ema has been tested several times, and has worked very well as a mid-term support level. Risk reward ratio is easy to set-up with a 3:1 ratio approximately. Sector & Industry Analysis It is important to note that the industries inside the sector have different performance, which has been very useful to analyze what the market thinks of the risk of healthcare with the election coming up. The following list is the Healthcare Industries with a 6-month performance % move, as well as a some good ETF to follow/trade: Healthcare Technology --> +56% // have not found appropriate ETF. Biotechnology --> +21% // XBI (smaller biotech), IBB (large-cap biotech), ARKG (genomics) Healthcare Equipment --> +19% // IHI Healthcare Providers --> +5.51% // IHF Pharmaceuticals --> -1.3% // IHE
AMEX:XLV
by dorfmanmaster
ALRN Weekend Data CatalystALRN had some weekend news. Will be interesting to see if it can break above a near-two-year resistance level. I didn't show it all the way back to November of 2018 but if you take the chart out further, you can see this level holding as resistance. "Saturday, the company announced new positive clinical data from its ongoing Phase 1b trial. The trial demonstrated clinical proof of concept that treatment with ALRN-6924 prior to second-line topotecan administration resulted in a protective effect against severe anemia, thrombocytopenia and neutropenia. This was in patients with p53-mutated small cell lung cancer. The results were featured in a late-breaking poster presentation entitled, 'Prevention of Chemotherapy-induced Myelosuppression in SCLC Patients Treated with Dual MDM2/MDMX Inhibitor ALRN-6924.'" Original Quote Source: 5 Penny Stocks On Robinhood To Buy Under $2; Are They Too Risky?
NASDAQ:ALRN
by PennyStocks101
MGEN Done Going Down Or Just A Pit Stop?MGEN has been getting hammered lately. Not one single green close in the last few weeks. Friday was the first, somewhat green close and that ain't saying much. But trading action was interesting. "riday’s action was something much different than what the penny stock had seen during the 2 weeks prior. It was the first trading day that MGEN shares didn’t close red. If you look at the chart, since October 9th, the penny stock saw a red close every day...Furthermore, trading action continued to push shares higher during after-hours on Friday." Original Quote Source: 5 Penny Stocks On Robinhood To Buy Under $2; Are They Too Risky?
M
by PennyStocks101
Make or Break Week For AXGT?AXGT is back at another area of support/resistance. Friday will be another day to keep in mind in light of the company's event. There will be additional data and program updates at its Parkinson’s disease R&D Day on Friday. Remember what was also said originally with this particular trial “These data, showing over 20 points of improvement on the UPDRS Part III ‘OFF’ motor function score, as well as meaningful improvements in quality of life measures, underscores the potentially best-in-class profile of AXO-Lenti-PD gene therapy in Parkinson’s disease. The totality of data seen thus far reinforces my belief that AXO-Lenti-PD has the potential to transform the treatment of patients with Parkinson’s disease through one-time administration of gene therapy.” - Gavin Corcoran, M.D., Chief R&D Officer at Axovant. Original Quote Source: 5 Biotech Penny Stocks To Watch With Recent & Upcoming Events
A
by PennyStocks101
High Traffic Pivots on CASI ChartCASI saw a nice bump in after-hours trading Friday. Shares hit $1.88. Can the Oppenheimer analyst rating be enough of a catalyst to carry through this momentum into the week ahead is the biggest question. Great volume on Friday but is it all for nothing? "What had sparked some excitement came in light of new analyst activity. Oppenheimer analyst Leland Gershell initiated coverage on CASI. The analyst gave it an Outperform rating and announced a price target of $5. That represents a 182% premium to Friday’s closing price for CASI stock." Original Quote Source: 5 Biotech Penny Stocks To Watch With Recent & Upcoming Events
NASDAQ:CASI
by PennyStocks101
Biotech etf catching up to the Qstested recently pitchfork upper line and bounced off..bullish sign. depending on timeframe but for this one BBC is catching up to the Qs. short term it looks just as over-exteneded as the Qs. trading will get very choppy short term. Disclaimer, this is only for entertainment and education purposes and doesn't serve by any means as a buy or sell recommendation. Personally I hold both long term long positions and occasionally short term short position, for disclosure purpose.
AMEX:BBC
by hanzhao311
2
BioNTech Stock Will Soar With Its First-Mover Vaccine AdvantageNASDAQ:BNTX a German company and its american partner NYSE:PFE will likely have a first-mover advantage in the coronavirus vaccine race in the U.S. This will affect both stocks, once the final vaccine results are in. Assuming the bottom is in and we are about to continue the Trend as previously, im expecting a big move after the approval, so dont forget to take risk of the table! The reason for this is that the two companies are expecting to be the first to produce large-scale results from their Phase 2/3 clinical trials in October, according to Barron’s. Depending on how effective their vaccine is, the U.S. Food and Drug Administration may even grant it emergency-use authorization The advantage of their trial is that it is large, involving more than 30,000 participants. The FDA wants to see at least 50% efficacy in trials before granting any Covid-19 authorization. Why BioNTechs Vaccine Looks Like a Winner With Pfizer in the back FDA and President Donald Trump are likely to move quickly. According to them even the first small study with 24 Persons that took their messenger RNA vaccine produced antibodies. With a lower doses usage of the vaccine and developed antibodies after 28 days — at levels about two times higher than in normal, recovering Covid-19 patients. BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech’s BNT162 to Hong Kong SAR and Macao SAR Also a Deal to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidat This combined with the huge buying volume and market shifts will grant momentum for bigger goals. Just think about what ccould happen when they get kinda a monopol situation going for them. Thank you for take the time and reading this and as always stay storng in those shaky times! Sebastian
NASDAQ:BNTXLong
by Sebastian-TradingExpertsEU
4
Ascending Triangle & Triple Bottom for CRSP?Notice the dark blue pattern on the chart, there's noticeably a Ascending Triangle and coincidentally a bullish inverted H&S where I have placed the green lines. Above each green line is appears to be a bottom, and there's three very noticeable on the line chart as opposed to the hollow candle chart. I have placed three blue finger icons so there is no confusion, each finger represents a bottom of the Triple Bottom. On the RSI there's was clearly a modest divergence, if the Ascending Triangle breakout to the upside the RSI is going to need to create a higher high and break out of the pattern to the upside negating the possibility of this ending in a bearish divergence & descending triangle.
NASDAQ:CRSPLong
by ScotianBot